[go: up one dir, main page]

WO2012025831A3 - Salmonella vaccine proteins - Google Patents

Salmonella vaccine proteins Download PDF

Info

Publication number
WO2012025831A3
WO2012025831A3 PCT/IB2011/002685 IB2011002685W WO2012025831A3 WO 2012025831 A3 WO2012025831 A3 WO 2012025831A3 IB 2011002685 W IB2011002685 W IB 2011002685W WO 2012025831 A3 WO2012025831 A3 WO 2012025831A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
salmonella spp
methods
salmonella vaccine
vaccine proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2011/002685
Other languages
French (fr)
Other versions
WO2012025831A2 (en
Inventor
B. Brett Finlay
Brian Coombes
Rosana Ferreira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of WO2012025831A2 publication Critical patent/WO2012025831A2/en
Publication of WO2012025831A3 publication Critical patent/WO2012025831A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compositions and methods for the treatment or prevention of Gram negative bacterial, such as Salmonella spp. infection, in a vertebrate subject are provided. The methods provide administering a composition to the vertebrate subject in an amount effective to reduce or eliminate the Salmonella spp. bacterial infection and/or induce an immune response to the protein. Methods for the treatment or prevention of Salmonella spp. infection in a vertebrate are also provided.
PCT/IB2011/002685 2010-08-24 2011-08-24 Salmonella vaccine proteins Ceased WO2012025831A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37661910P 2010-08-24 2010-08-24
US61/376,619 2010-08-24

Publications (2)

Publication Number Publication Date
WO2012025831A2 WO2012025831A2 (en) 2012-03-01
WO2012025831A3 true WO2012025831A3 (en) 2012-05-03

Family

ID=45723860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/002685 Ceased WO2012025831A2 (en) 2010-08-24 2011-08-24 Salmonella vaccine proteins

Country Status (1)

Country Link
WO (1) WO2012025831A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
WO2009130618A2 (en) * 2008-04-25 2009-10-29 Institute For Systems Biology Flagellin polypeptide vaccines
WO2010003219A1 (en) * 2008-06-17 2010-01-14 Universite Laval Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines
US20100111903A1 (en) * 2003-09-19 2010-05-06 Emery Daryll A Compositions produced using enteric pathogens and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US20100111903A1 (en) * 2003-09-19 2010-05-06 Emery Daryll A Compositions produced using enteric pathogens and methods of use
WO2009130618A2 (en) * 2008-04-25 2009-10-29 Institute For Systems Biology Flagellin polypeptide vaccines
WO2010003219A1 (en) * 2008-06-17 2010-01-14 Universite Laval Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines

Also Published As

Publication number Publication date
WO2012025831A2 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
WO2012092469A3 (en) Clostridium difficile antigens
WO2012003474A3 (en) Compositions and methods related to protein a (spa) variants
WO2011110655A3 (en) Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease
WO2011152566A3 (en) Composition for inducing proliferation or accumulation of regulatory t cells
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
MX350325B (en) Bacterium for use as a probiotic for nutritional and medical applications.
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2012097185A3 (en) Omv vaccine against burkholderia infections
IN2012DN01898A (en)
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
AU2018256482A1 (en) Antibodies Against Clostridium Difficile
PH12013501437A1 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
UA111599C2 (en) COMPOSITION OF CASPOFUNGIN
NZ594019A (en) Novel antibacterial agents for the treatment of gram positive infections
WO2012061248A3 (en) Novel specific hcv ns3 protease inhibitors
WO2013084070A3 (en) Salmonella vaccine proteins
WO2009115509A3 (en) Antigenic protein fragments of streptococcus pneumoniae
WO2014167582A3 (en) Vaccine composition for prophylaxis in ruminants
WO2011009042A3 (en) Antigen compositions and methods of inhibiting campylobacter jejuni bacterial infection and uses of the antigen compositions
HK1199201A1 (en) Antimicrobial peptides for treatment of infectious diseases
WO2011084967A3 (en) Methods and compositions for providing protective immunity in the elderly
MY170190A (en) Use of a fermented soy extract as a prebiotic composition
WO2012025831A3 (en) Salmonella vaccine proteins
PH12012502253A1 (en) Oral care compositions and methods
WO2012075104A3 (en) Novel non-primate hepacivirus

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11819485

Country of ref document: EP

Kind code of ref document: A2